Yoshitaro Torii

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Statins, inhibitors of 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production

Hideki Amuro, Tomoki� Ito, Rie Miyamoto et al. · Arthritis & Rheumatism · 2010 · 50 citations · Full text

Hodgkin’s Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells

Tsutomu Tanijiri, Toshiki Shimizu, Kazutaka Uehira et al. · Journal of Leukocyte Biology · 2007 · 46 citations · Full text

Lymphocyte Development, T-regulatory Cell, Immunology +21

Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer

Aya Nakaya, Takayasu Kurata, Takashi Yokoi et al. · Cancer Medicine · 2016 · 38 citations · Full text

Imidazoquinoline Acts as Immune Adjuvant for Functional Alteration of Thymic Stromal Lymphopoietin-Mediated Allergic T Cell Response

Yoshitaro Torii, Tomoki� Ito, Ryuichi Amakawa et al. · The Journal of Immunology · 2008 · 24 citations